In case you haven't heard, EpiPens are costing a fortune, and everyone is upset about it. Costs for this emergency allergy treatment have escalated more than 400% for the price of just two pens. Joining the ranks of outraged consumers and allies is Sarah Jessica Parker. In a statement on Thursday, the actress announced she will "no longer be associated with the drugmaker who manufactures it."
According to USA Today, the price of the EpiPen has climbed to $608 this year, which is significant, considering the pen cost only $57 back in 2007.
Parker took to her Instagram account with an official statement detailing her reasons and concern "for Mylan's actions." She went on to say she was "recently involved in an initiative to raise awareness for anaphylaxis," but due to the even more recent controversy and price increases for the treatment pen, she does "not condone this decision" and has decided to cut ties with the company.
Parker's son James is only 13-years-old, and has struggled with peanut and hazelnut allergies all of his life.
While EpiPen makers have since announced their intent to offer discount coupons "covering up to $300," the cost will still be too much for some. The new "discount," they say, is meant "for patients in health plans who face higher out-of-pocket costs."
Mylan also announced it would "double the income level at which families are eligible for assistance in purchasing the medication." This means they would raise their policy threshold to 400% of the federal poverty level, which currently stands at around $24,300 for a family of four.
"As a mother, I can assure you, the last thing that we would ever want is no one to have their EpiPen due to price," Mylan CEO Heather Bresch said on CNBC in an interview. "Our response has been to take that immediate action of making sure everyone has an EpiPen."
Unfortunately, these discounts and policy changes will not effect the market price of the EpiPen, which will still cost upwards of $600.
There is currently no generic equivalent or brand-name competitor.